October #64 : Take Five - by Staff

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Stephen Gendin

Be Very Afraid

The CD4 Solution?

The Boys in the Band

Bare Witness

The March

My, What a Big Trial IL-2 Has! Will It Work?

AIDSplotation or Art?

Refugee All-Stars

Drive-By Shopping

Upward Mobility



Take Five

POZ Picks

The Medium Is The Message

A Conference Of Their Own


Cutting Class

Last Word

It Takes A Village Voice

Conference of the Century

Stop and Start

Sit Up, Sit Down?

Too Much Information

Sex RX

Talking Tipranavir

Shelf Life

The In Crowd

Herb Of The Month

He Died Of Old AIDS

10.8.88: Old Flames

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

October 2000

Take Five

by Staff

In May, UNAIDS urged five companies to say they’d cut the prices of anti-HIV drugs in poor countries. After many press releases (and even more free publicity), few additional details have been released. A brief look at the facts and possible pitfalls:

Boehringer-Ingelheim, Germany
Price Tag: TBA
Active Ingredients: Five years of free nevirapine, but only to prevent mom-to-babe transmission. Countries must ask for the drug and meet the World Bank’s definition of a developing nation in order to avoid any coloniastic overtones.
Warning: But hey, it only covers mothers and kids using the drug, not other HIVers.

Bristol-Meyers Squibb, U.S.
Price Tag: $100 mil over five years (started in 99)
Active Ingredients: “Secure the Future” program targets women and children in South Africa, Botswana, Namibia, Lesotho, and Swaziland; generally credited with setting a good example for other drug companies.
Warning: Locals say that they want more community initiatives and lower drug prices, not phsician trainings and clinical trials.

Glaxo Wellcome, Great Britain
Price Tag: TBA
Active Ingredients: Price cuts for Combivir, from $16 to $2 per day in developing nations, and a free start-up supply of AZT for pregnant women.
Warning: Activists say even $2 is more than the 40 cents it costs to make the drug generically. And once the initial cache of AZT is used, moms will have to pay, too.

Merck & Co., INC., US
Price Tag: $50 mil
Active Ingredients: The Gates Foundation will match the donation to improve medical infrastructure in Botswana. Crixivan and Sustiva will be offered free in 2001.
Warning: We’re waiting to find out how many people will get the drugs.

Roche Labs, Switzerland
Price Tag: TBA
Active Ingredients: Countries to provide Fortovase, Ivirase, and Vireacept at a reduced (undisclosed) cost in some nations, say reps.
Warning: No other details had been released at press time.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.